Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

Wed, 21st Apr 2021 07:52

(Alliance News) - Stock prices in London are seen opening slightly higher on Wednesday, rebounding from steep falls on Tuesday, as a surge in coronavirus cases in countries including India and Japan weighs on investor sentiment.

In early company news, distribution firm Bunzl reported a rise in revenue in the first quarter. Generic drugmaker Hikma Pharmaceuticals resumed the launch of its Advair Diskus treatment in the US. Chilean copper miner Antofagasta left annual production guidance unchanged, but Anglo-Australian BHP reduced guidance for coal production.

IG futures indicate the FTSE 100 index is to open 9.93 points higher at 6,869.80. The blue-chip index closed down 140.21 points, or 2.0%, at 6,859.87 Tuesday.

Bunzl said its "diversified and resilient" business model delivered good overall growth amid continuing pandemic-related challenges during the first quarter of 2021.

Revenue was up 5.4% at actual exchange rates and 10% at constant exchange rates. Underlying revenue growth at constant exchange rates increased by 1.4%, in line with expectations.

In addition, Bunzl said adjusted operating margin continued to be supported by demand for Covid-19 related products. The company delivered personal protective equipment to businesses during the pandemic.

Looking ahead, Bunzl said guidance remains unchanged. At constant exchange rates, Bunzl continues to expect robust revenue growth in 2021 compared to the prior year, after excluding larger Covid-19 related orders, which contributed GBP550 million of revenue in 2020.

"A recovery in sales of other products is expected to be largely offset by a decline in smaller Covid-19 related orders, while recent acquisitions will further contribute to the group's performance in 2021. After excluding larger Covid-19 related orders, the group continues to expect good organic revenue growth in the first half of 2021 to be followed by a moderate decline in the second half. Group adjusted operating margin for the year is expected to return to a more historical level," Bunzl said.

Hikma Pharmaceuticals said it has that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus in the in the US.

The move follows the US Food & Drug Administration's approval of an amendment that Hikma had submitted to its Abbreviated New Drug Application in January. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its application, Hikma said.

Chief Executive Officer Siggi Olafsson said: "We appreciate the FDA's timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus. We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US."

Antofagasta said copper production in the first quarter was in line with guidance at 183,000 tonnes, 5.7% lower than in the same quarter in 2020 and 5.0% lower than in the fourth quarter, mainly due to expected reduced grades at the Los Pelambres mine.

Gold production was 59,100 ounces in the first quarter, 9.2% lower than in the same period in 2020 and 8.0% higher than in the fourth quarter, mainly due to changes in grade at the Centinela mine.

Looking ahead, Antofagasta said full-year guidance is unchanged at 730 tonnes to 760,000 tonnes of copper at a net cash cost of USD1.25 per pound and capital expenditure of USD1.6 billion.

CEO Ivan Arriagada said: "Labour negotiations were successfully concluded at Los Pelambres and no further negotiations are scheduled at our mining operations until next year.

"The copper market continues to perform strongly, and we expect this to continue as structural supply and demand dynamics support a tight physical market. In the meantime, we maintain our focus on cost control and disciplined capital allocation. Production, cost and capital expenditure guidance for the full year is unchanged, assuming no additional nationwide restrictions are imposed due the pandemic."

BHP lowered guidance for coal production after wet weather hit operations.

The miner said copper production in the first quarter of 2020 fell 8% year-on-year to 391,400 tonnes. Petroleum production increased 1% compared to the year before to 25.4 million barrels of oil equivalent. Iron ore production was flat to the prior year.

Metallurgical coal production increased 4% year-on-year to 9.6 million tonnes, while energy coal production sank 17% to 4.8 million tonnes. Nickel production slipped 2% year-on-year to 20,400 tonnes.

Going forward, full-year production guidance for petroleum, nickel and iron ore was left unchanged, but it was lowered for metallurgical and energy coal.

In Tokyo, the Nikkei 225 index closed down 2.0% on Wednesday. In China, the Shanghai Composite was up 0.1%, while the Hang Seng index in Hong Kong was down 1.8%. The S&P/ASX 200 in Sydney closed 0.6% lower.

"Markets in Asia have seen weakness this morning, with the Nikkei falling especially sharply, following on from yesterday's slide in Europe and the US, with markets in Europe expected to open mixed," said CMC Markets analyst Michael Hewson.

The EU will have enough Covid-19 vaccine doses to cover 70% of its adult population by mid-July due to higher production within the bloc, a senior official said Tuesday.

"Fifty-three factories are producing vaccines in the EU. Our continent is now the largest producer in the world after the US," internal markets commissioner Thierry Breton told French daily Le Figaro in an interview.

"I am now certain of how many doses are currently in production and I know how many millions will be delivered each week," he said. "This allows me to assure you that we well have by mid-July the number of doses necessary for vaccinating 70% of the EU's adult population," he said, citing the threshold many health experts say is necessary to achieve "herd immunity".

The pound was quoted at USD1.3945 early Wednesday, flat on USD1.3940 at the London equities close Tuesday.

The euro was priced at USD1.2030, down from USD1.2035. Against the yen, the dollar was quoted at JPY108.01, flat from JPY108.03.

Brent oil was trading at USD66.20 a barrel Wednesday morning, up from USD65.71 late Tuesday. Gold was quoted at USD1,786.71 an ounce, higher from USD1,776.45.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
6 Mar 2023 09:48

LONDON BROKER RATINGS: DB cuts Reckitt; Jefferies likes Tesco

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
1 Mar 2023 09:52

LONDON BROKER RATINGS: Canaccord says sell Future; Investec likes RWS

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
27 Feb 2023 09:38

Berenberg raises target price on Hikma Pharmaceuticals

(Sharecast News) - Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Read more
27 Feb 2023 09:26

LONDON BROKER RATINGS: Citi cuts Quilter to 'sell'; Goldman likes GSK

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
24 Feb 2023 09:37

LONDON BROKER RATINGS: SocGen cuts Burberry; BofA cuts WH Smith

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
23 Feb 2023 09:54

Hikma Pharmaceuticals profit halves in 2022 on Generics impairment

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported a dip in annual revenue for 2022, as profit tumbled due to high inflation and adjustments regarding expectations for its Generics business.

Read more
23 Feb 2023 09:02

LONDON MARKET OPEN: Mixed open in London; Rolls-Royce up, Mondi down

(Alliance News) - Stock prices in London opened mixed on Thursday, with large-cap indices underperforming amid mixed corporate earnings.

Read more
23 Feb 2023 07:59

Competition in generics sees Hikma Pharmaceuticals's profits decline by a tenth

(Sharecast News) - Hikma Pharmaceuticals posted lower full-year profits as stiff competition in generics saw its top line growth flatten out.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.